News and Trends 5 Apr 2017 Heptares Takes Home €11M for its Next-Generation Checkpoint Inhibitor Heptares Therapeutics has achieved a new milestone in its immuno-oncology collaboration with AstraZeneca triggering an €11M payment from AstraZeneca. Heptares has announced the wrap-up of its preclinical programme for a new checkpoint inhibitor, AZD4635 that reverses adenosine-mediated T cell suppression and enhances anti-tumor immunity. The British company will now receive an €11M ($12M) milestone payment from AstraZeneca, who obtained exclusive global rights […] April 5, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 5 Apr 2017 Planning a Clinical Trial – Think Smart Design By using smart designs, sponsors can save time and money while optimizing the knowledge accrued during the development of their products. “Traditional” study designs and statistical methodology do not allow changing the main features of a study protocol once the study has been initiated. The use of interim analyses, and in particularly the development of […] April 5, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 4 Apr 2017 Sample a More Efficient Sorbent to Streamline your mAb Purification Need an efficient way to purify your antibodies but struggle to find the best column? Pall Life Sciences is giving you the opportunity to try their solution for free. Enter your email below and receive your KANEKA Protein A sorbent sample! Pall Life Sciences is giving you a chance to try for free the new, […] April 4, 2017 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2017 Massive €800M Acquisition of Belgian Biotech treating Menopause Astellas Pharma is acquiring Ogeda, getting hold of its promising Phase II candidate to treat menopause without hormonal therapy. After acquiring Ganymed Pharmaceuticals last October for a record €1.3B in German biotech, the Japanese Astellas Pharma is making a second massive acquisition in Europe. Its new addition is Ogeda, a Belgian biotech targeting GPCRs to treat gynecological […] April 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2017 New Results Show GM Mosquitoes Keep Dengue and Zika at Bay in Brazil In its second year, Oxitec has reduced the mosquito population in a Brazilian neighborhood by 81%, demonstrating the long-term potential of GM insects. Oxitec is a spin-out from the University of Oxford that fights infectious disease with genetically-engineered mosquitoes that produce inviable offspring. The company has already made field trials in the Cayman Islands, Panama, Brazil, […] April 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2017 UPDATE: First Woman CEO of a Global Drug Maker starts at GSK today GSK has punched a hole in the glass ceiling with its appointment of a new female CEO, Emma Walmsley. It’s up to her to reinvigorate the company. Emma Walmsley may be the most powerful woman in corporate Britain. The Oxford grad and L’Oreal veteran has just been crowned CEO of the pharma giant GSK: a marketing […] April 3, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2017 French Synbio Company gets ready to break into Cosmetics After biofuels and carotenoids, Deinove is now moving forward on the cosmetics front. Its engineered microbes can produce a number of interesting chemicals for skin care, and Deinove plans to bring them to market until the end of 2018. Deinove is a key synbio biotech in France and has found a wide range of applications for […] March 31, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 30 Mar 2017 New Clues on How the Immune System Weakens with Age By analyzing the responses of individual immune cells, a new study in Science provides new insights into the decline of the immune system with age. In a collaborative effort, researchers from the European Bioinformatics Institute (EMBL-EBI), University of Cambridge, the Wellcome Trust Sanger Institute and the Cancer Research UK–Cambridge Institute (CRUK-CI) have shed light on a […] March 30, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 30 Mar 2017 Merck Outsources the Development of its Nanobody for Psoriasis Merck has signed a new agreement with Avillion for its nanobody against psoriasis. Avillion will advance the nanobody from Phase II through Phase III. As part of several partnerships between Merck and the unbeaten nanobody biotech Ablynx, Merck recently cleared Phase Ib with its llama-inspired nanobody targeting the cytokines IL-17 A/F for the treatment of plaque psoriasis. The antibody […] March 30, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 29 Mar 2017 Get Ready for One of the Biggest New Drug Approvals of the Year After Praluent, Sanofi and Regeneron have now scored their next drug approval with dupilumab, an antibody for the treatment of atopic dermatitis. With three placebo-controlled clinical trials enrolling a total of 2119 adult participants, Sanofi and its partner Regeneron were able to convince the FDA of their new biological for the treatment of atopic dermatitis. The product of this expansive effort comes […] March 29, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 29 Mar 2017 French Gene Therapy Biotech Gets Ready for Phase II/III Lysogene has crunched the numbers on its observational study for Sanfillipo A – now the company can move into the final phase for its Sanfilippo A therapy. Lysogene is a French biotech specializing in gene therapy of rare CNS diseases. Its lead asset is a gene therapy for the treatment of the rare genetic disorder […] March 29, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 29 Mar 2017 Looking to Patent your Biotech Invention? Here’s What You Need to Know So you’ve made a discovery you want to protect or an invention you want to commercialize. How do you claim intellectual property? Patents are the most relevant kind of intellectual property protection for technology-driven industries, particularly high-tech startups. They grant intellectual property rights covering technical inventions and relate to compositions, processes or methods of making these, or their use for a particular purpose. More […] March 29, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email